Capricor Therapeutics, Inc.(CAPR)

Biotechnology · San Diego, CA

$7.75-0.03 (-0.39%)

Delayed quote: Oct 6, 2026, 4:00 PM EDT

EV/EBIT Ratio: N/A

Basis: Current FMP quote-based enterprise value / four-quarter operating income. Source: stored company filings and market data; unavailable inputs remain N/A.

The EV/EBIT ratio is N/A as of 2026-10-06T21:41:04.333Z.

Stored calculation inputs

Calculation as of: 2026-10-06T21:41:04.333Z.

Quote observation: 2026-10-06T20:00:01.000Z. Amounts in USD. The price header may show a later quote.

Quote market capitalization: 445,707,421
Total debt · period ending 2026-06-30: 91,045,362
Cash · period ending 2026-06-30: 20,935,187
TTM operating income · period ending 2026-06-30: -135,160,121

FMP input reference: e0d40f2287a6df540829b60f0e5c7cec39727eaf24e7e990ba5054a2dfdba9d9

EV/EBITDA|EV/Sales|Operating Income|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

CAPR EV/EBIT Ratio Metrics

EV/EBIT RATIO

N/A

CAPR Competitors' EV/EBIT Ratio

CAPR

Capricor Therapeutics, Inc.

Current

Market Cap

$445.71M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

OVID

Ovid Therapeutics Inc.

vs CAPR

Market Cap

$442.34M

EV/EBIT Ratio

N/A

TTM Avg

0.21x

3Y Avg

0.21x

5Y Avg

0.21x

ASMB

Assembly Biosciences, Inc.

vs CAPR

Market Cap

$439.55M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NRC

NRC Health

vs CAPR

Market Cap

$452.54M

EV/EBIT Ratio

36.59x

TTM Avg

22.84x

3Y Avg

18.67x

5Y Avg

19.86x

DMAC

DiaMedica Therapeutics Inc.

vs CAPR

Market Cap

$438.07M

EV/EBIT Ratio

N/A

TTM Avg

84.81x

3Y Avg

33.20x

5Y Avg

21.83x

YDES

YD Bio Limited Ordinary Shares

vs CAPR

Market Cap

$435.61M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NPCE

NeuroPace, Inc.

vs CAPR

Market Cap

$431.97M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

SPRY

ARS Pharmaceuticals, Inc.

vs CAPR

Market Cap

$426.51M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

SGHT

Sight Sciences, Inc.

vs CAPR

Market Cap

$465.75M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NEO

NeoGenomics, Inc.

vs CAPR

Market Cap

$424.10M

EV/EBIT Ratio

N/A

TTM Avg

64.08x

3Y Avg

60.43x

5Y Avg

132.37x

NAME	MARKET CAP	EV/EBIT RATIO	TTM	3Y	5Y
Capricor Therapeutics, Inc. (CAPR)	$445.71M	N/A	N/A	N/A	N/A
Ovid Therapeutics Inc. (OVID)vs ›	$442.34M	N/A	0.21x	0.21x	0.21x
Assembly Biosciences, Inc. (ASMB)vs ›	$439.55M	N/A	N/A	N/A	N/A
NRC Health (NRC)vs ›	$452.54M	36.59x	22.84x	18.67x	19.86x
DiaMedica Therapeutics Inc. (DMAC)vs ›	$438.07M	N/A	84.81x	33.20x	21.83x
YD Bio Limited Ordinary Shares (YDES)vs ›	$435.61M	N/A	N/A	N/A	N/A
NeuroPace, Inc. (NPCE)vs ›	$431.97M	N/A	N/A	N/A	N/A
ARS Pharmaceuticals, Inc. (SPRY)vs ›	$426.51M	N/A	N/A	N/A	N/A
Sight Sciences, Inc. (SGHT)vs ›	$465.75M	N/A	N/A	N/A	N/A
NeoGenomics, Inc. (NEO)vs ›	$424.10M	N/A	64.08x	60.43x	132.37x

EV/EBIT Ratio Formula & Definition

EV/EBIT = Enterprise Value / EBIT (TTM)

Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

EV/EBIT Ratio: N/A

CAPR EV/EBIT Ratio Metrics

CAPR Competitors' EV/EBIT Ratio

EV/EBIT Ratio Formula & Definition

Related Metrics